Wellbutrin (Bupropion) Does NOT Increase Bleeding Risk When Combined with Plavix (Clopidogrel)
Bupropion (Wellbutrin) is not associated with increased bleeding risk when taken with clopidogrel (Plavix). The bleeding risk you need to worry about comes from Plavix itself, not from any interaction with Wellbutrin.
Understanding the Real Bleeding Risk
Plavix alone increases bleeding risk because it is an antiplatelet agent that inhibits platelet aggregation for the lifetime of the platelet (7-10 days) 1. This is the medication's intended mechanism of action, not a drug interaction issue.
Baseline Bleeding Rates with Plavix:
- Clopidogrel alone: Associated with GI bleeding risk, though lower than aspirin (2.0% vs 2.7%) 2
- Dual antiplatelet therapy (Plavix + aspirin): Increases bleeding 2- to 3-fold compared to aspirin alone, with absolute risk increases of 0.6-2.0% 2
- Major bleeding rates: 2.7-3.7% in acute coronary syndrome trials 2, 3
The Wellbutrin-Plavix Interaction: Metabolic, Not Bleeding-Related
The documented interaction between these medications involves drug metabolism through CYP2B6, not bleeding risk 4. Specifically:
- Clopidogrel inhibits CYP2B6, the enzyme that metabolizes bupropion
- This reduces bupropion's conversion to hydroxybupropion by 52% 4
- The result: increased bupropion levels (60% higher AUC) 4
Clinical Implications of This Metabolic Interaction:
- You may need to adjust bupropion dosing downward if side effects emerge (anxiety, insomnia, tremor, seizure risk at high levels)
- This is about bupropion toxicity risk, not bleeding
- Monitor for bupropion-related adverse effects, particularly neuropsychiatric symptoms
What Actually Increases Bleeding Risk with Plavix
Focus your attention on these definite risk factors 2, 1:
High-Risk Factors:
- Prior GI bleeding history (strongest predictor) 2
- Concomitant aspirin use: Increases major bleeding OR 2.83 (95% CI 2.04-3.94) 5
- Anticoagulants (warfarin, DOACs): Substantially increases bleeding 6, 1
- NSAIDs and chronic NSAID use 2, 1
- Corticosteroids 2
Moderate-Risk Factors:
- Advanced age 2
- Duration of therapy >6 months (OR 1.74,95% CI 1.21-2.50) 5
- Helicobacter pylori infection 2
Medications That Affect Bleeding Through CYP2C19:
- SSRIs/SNRIs: Listed as bleeding risk factors 1
- Strong CYP2C19 inducers: May potentiate bleeding by increasing active metabolite levels 1
Common Pitfall to Avoid
Do not confuse metabolic drug interactions with bleeding risk. The fact that clopidogrel affects bupropion metabolism does not translate to increased bleeding. High-throughput pharmacoepidemiologic screening of clopidogrel interactions identified 28 drug pairs associated with serious bleeding 7, and bupropion was not among them.
Practical Management
Continue both medications without concern for bleeding interaction, but:
Monitor for bupropion side effects (the actual interaction concern)
Assess true bleeding risk factors using the list above
Consider PPI prophylaxis if patient has:
Do NOT routinely use PPIs in low-risk patients 2
The 2010 ACCF/ACG/AHA consensus explicitly states that bleeding risk management should focus on established risk factors like anticoagulants, NSAIDs, and prior bleeding history 2—not on medications like bupropion that lack antiplatelet or anticoagulant properties.